NCT05063721View on ClinicalTrials.gov

MABs Therapy m.3243A>G Mutation Carriers

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 1, 2020

Primary Completion Date

September 16, 2022

Study Completion Date

December 1, 2022

Conditions
Mitochondrial Myopathies
Interventions
BIOLOGICAL

autologous mesoangioblasts

intra-arterial administration of autologous mesoangioblasts in lower leg (50x10E6/kg)

Trial Locations (1)

Unknown

Maastricht University, Maastricht

All Listed Sponsors
lead

Maastricht University

OTHER

NCT05063721 - MABs Therapy m.3243A>G Mutation Carriers | Biotech Hunter | Biotech Hunter